Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).
Yaman
E
E
Benekli
M
M
Coskun
U
U
Ozturk
B
B
Kaya
A O
AO
Yildiz
R
R
Buyukberber
S
S
D000284:Administration, Oral; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D015331:Cohort Studies; D024042:Collagen Type I / Q000097:blood / Q000187:drug effects; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D007093:Imidazoles / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D015675:Osteocalcin / Q000097:blood; D010455:Peptides / Q000097:blood / Q000187:drug effects; D011347:Procollagen / Q000097:blood / Q000187:drug effects; D011379:Prognosis; D012680:Sensitivity and Specificity; D000077211:Zoledronic Acid
D014408:Biomarkers, Tumor; D024042:Collagen Type I; D004164:Diphosphonates; D007093:Imidazoles; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D000077211:Zoledronic Acid; D000077557:Ibandronic Acid